Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | HCN1 | O60741 | 1/20 | 0.40 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12049730 | 0.69 | SCN1A (0.49) | RAB9ANPC1TP53MC4RHRH4 | |
| SCHEMBL3938379 | 0.67 | RAB9A (0.36) | RAB9ANPC1TP53MC4RHCN1 | |
| SCHEMBL20892082 | 0.66 | MC4R (0.53) | RAB9ANPC1TP53MC4RHRH4 | |
| N-Methylpiperidine SCHEMBL27872310 | 0.63 | MC4R (0.53) | RAB9ANPC1TP53MC4RHRH4 | |
| SCHEMBL14279644 | 0.63 | GAA (0.55) | MC4RHCN1HCN4SIGMAR1 | |
| SCHEMBL3600511 | 0.61 | — | — | |
| SCHEMBL24673292 | 0.61 | MEN1 (0.66) | RAB9ANPC1HRH3SIGMAR1 | |
| SCHEMBL2607031 | 0.61 | MEN1 (0.66) | RAB9ANPC1HRH3SIGMAR1 | |
| SCHEMBL2085642 | 0.61 | MC4R (0.69) | RAB9ANPC1TP53MC4RSIGMAR1 | |
| SCHEMBL19567595 | 0.61 | CCR6 (0.36) | RAB9ANPC1TP53MC4RHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | disclosed |
| US-20050222171-A1 | Organic compounds | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222171-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | RAB9A 1730/4885NPC1 1185/4885TP53 659/4885 |
| US-20090099167-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | RAB9A 1730/4885NPC1 1185/4885TP53 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.